🇺🇸 FDA
Patent

US 8450341

Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8450341 (Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors) held by Almirall, S.A. expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Almirall, S.A.
Grant date
Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P1/00, A61P1/04, A61P11/00, A61P11/16